General
Preferred name
FENOFIBRATE
Synonyms
Procetofen ()
Lipanthyl ()
Lipantil ()
Tricor / Trilipix ()
NSC-281319 ()
Fenofibrate (NSC-281319) ()
Lipidil ()
Lipofen ()
Fenofibrato ()
Lipantil Micro 67 ()
Antara ()
Lipantil Micro 267 ()
Fenoglide ()
Lipantil Micro 200 ()
Tricor ()
Supralip 160 ()
Tricor (micronized) ()
Antara (micronized) ()
Fenogal ()
Triglide ()
Fenofibrate micronized ()
Fenofibrate delayed release ()
Fenofibrate (micronized) ()
Fenofibrate-d6 ()
P&D ID
PD001506
CAS
49562-28-9
1092484-56-4
Tags
available
probe
prodrug
drug
Approved by
EMA
FDA
First approval
1993
Drug indication
High cholesterol level
Cardiovascular disease
Drug Status
approved
Max Phase
4.0
Probe info
Probe type
calculated probe
Probe selectivity
protein-selective
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Fenofibrate is an antilipemic agent. Combination drug formulations often contain statins. (GtoPdb)
PRICE 29
DESCRIPTION Fenofibrate is a selective PPAR¦Á agonist with an EC50 of 30 ¦ÌM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 ¦ÌM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
DESCRIPTION Fenofibrate (Lipanthyl) is a PPAR?? agonist (EC50=30 ??M) and is selective. Fenofibrate also inhibits cytochrome P450 isoforms, such as CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4. Fenofibrate exhibits antihyperlipidemic activity.
DESCRIPTION Synthetic corticosteroid; anti-inflammatory agent (Tocris Bioactive Compound Library)
DESCRIPTION PPARalpha agonist (Tocriscreen Plus)
DESCRIPTION PPAR-alpha receptor agonist; lipid regulating drug (LOPAC library)
DESCRIPTION Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercholesterolemia and hypertriglyceridemia. (BOC Sciences Bioactive Compounds)
DESCRIPTION Fenofibrate is a fibrate that activates peroxisome proliferator activated receptor alpha (PPARα) to alter lipid metabolism and treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. (Enamine Bioactive Compounds)
DESCRIPTION Fenofibrate (Lipanthyl) is a PPARα agonist (EC50=30 μM) and is selective. Fenofibrate also inhibits cytochrome P450 isoforms, such as CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4. Fenofibrate exhibits antihyperlipidemic activity. (TargetMol Bioactive Compound Library)
Cell lines
4
Organisms
1
Compound Sets
40
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
ZINC Tool Compounds
External IDs
60
Properties
(calculated by RDKit )
Molecular Weight
360.11
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
2
Aromatic Ring Count
2
cLogP
4.68
TPSA
52.6
Fraction CSP3
0.3
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Custom attributes
(extracted from source data)
Target Type
Nuclear Receptors
Selectivity
PPAR-alpha
Pathway
Autophagy
DNA Damage/DNA Repair
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Primary Target
PPAR?
MOA
Agonist
APOA1 Expression Enhancers
PPARalpha Agonists
PPAR receptor agonist
Member status
member
Indication
hypercholesterolemia, hypertriglyceridemia
Target
MMP25, PPARA
Cytochrome P450
PPAR
Autophagy,P450 (e.g. CYP17),PPAR
CYP2B6
CYP2C
CYP2C19
PPARα
Therapeutic Indication
Dyslipidemia
Therapeutic Class
Cardiovascular
Antilipemic Agents
Source data